Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2021 21:45 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock...
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
November 17, 2021 08:00 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19...
Zosano Pharma Reports Third Quarter 2021 Financial Results
November 10, 2021 16:10 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended...
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
October 04, 2021 08:00 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written...
Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
September 02, 2021 16:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive...
Zosano Pharma Reports Second Quarter 2021 Financial Results
August 10, 2021 16:05 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended...
Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
July 20, 2021 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has been granted an additional patent...
Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
May 26, 2021 16:05 ET
|
Zosano Pharma Corporation
FREMONT, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety,...
Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
May 25, 2021 16:05 ET
|
Zosano Pharma Corporation
FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished...
Zosano Pharma Reports First Quarter 2021 Financial Results
May 12, 2021 16:05 ET
|
Zosano Pharma Corporation
FREMONT, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended...